{"created":"2021-03-01T06:12:32.168245+00:00","id":8515,"links":{},"metadata":{"_buckets":{"deposit":"2872bc80-c905-4fb8-882d-a2537ac8ebc2"},"_deposit":{"id":"8515","owners":[],"pid":{"revision_id":0,"type":"depid","value":"8515"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00008515","sets":["453:456","471:537:538:903"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Tocilizumab，　Abatacept　and　Tofacinib"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"11","bibliographicPageStart":"9","bibliographicVolumeNumber":"130","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"関節リウマチの治療は, 近年, 飛躍的な進歩を遂げている. 2014年, 日本国内で生物学的製剤としてはTNF-α阻害薬, IL-6受容体拮抗薬, 細胞障害性Tリンパ球関連蛋白(CTLA)-4融合蛋白が, 分子標的薬としてはJanus kinase (JAK)阻害薬が臨床使用されている. 本稿ではIL-6受容体拮抗薬, CTLA-4融合蛋白, JAK阻害薬について概説する. これらの薬剤は関節リウマチ患者に福音をもたらす可能性がある一方, 重篤な感染症や悪性腫瘍などの懸念があり, 適応をよく検討した上で使用する必要がある.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"59250","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Nakatsue, Takeshi"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"中枝, 武司"}],"nameIdentifiers":[{"nameIdentifier":"59249","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-06"}],"displaytype":"detail","filename":"130(1)_9-11.pdf","filesize":[{"value":"210.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"130(1)_9-11.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/8515/files/130(1)_9-11.pdf"},"version_id":"3a373fa1-c562-491e-aeca-2d9cddb1d648"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"関節リウマチ","subitem_subject_scheme":"Other"},{"subitem_subject":"トシリズマブ","subitem_subject_scheme":"Other"},{"subitem_subject":"アバタセプト","subitem_subject_scheme":"Other"},{"subitem_subject":"トファシチニブ","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"3 その他の生物学的製剤(シンポジウム 関節リウマチの治療の進歩, 第702回新潟医学会 )","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"3 その他の生物学的製剤(シンポジウム 関節リウマチの治療の進歩, 第702回新潟医学会 )"},{"subitem_title":"3 その他の生物学的製剤(シンポジウム 関節リウマチの治療の進歩, 第702回新潟医学会 )","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","903"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-10-14"},"publish_date":"2016-10-14","publish_status":"0","recid":"8515","relation_version_is_last":true,"title":["3 その他の生物学的製剤(シンポジウム 関節リウマチの治療の進歩, 第702回新潟医学会 )"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:42:50.713303+00:00"}